Physician
Pinnacle Pain Center, PS
Pinnacle Pain Center, PS was paid $11.61M by Medicaid between Jan 2018 and Aug 2023, across 47 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 38% of everything it billed.
33Billing provider infoPINNACLE PAIN CENTER, PS
KENNEWICK, WA 99336
KENNEWICK, WA 99336
33aNPI1740434356assigned 11/10/2008
33bProvider typeInterventional Pain Medicine Physician
28Total paid$11.61M
24GClaims210,715
24DCodes billed47
24AFirst – last monthJan 2018 – Aug 2023
Compared with peers
Next to other Interventional Pain Medicine Physician providers in Washington
Rank by total paid#1 of 6
Median peer was paid$13K
This provider vs. median880×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 34,041 | $1.86M | |
| 2019 | 43,423 | $2.62M | |
| 2020 | 37,884 | $2.32M | |
| 2021 | 41,909 | $2.13M | |
| 2022 | 38,128 | $1.87M | |
| 2023 | 15,330 | $815K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 38% | 100,776 | 89,870 | $4.45M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 24% | 23,532 | 21,267 | $2.84M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 20% | 42,892 | 38,044 | $2.30M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 7.6% | 6,614 | 5,807 | $884K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.8% | 2,209 | 1,974 | $214K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1.6% | 2,615 | 2,510 | $191K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 1.6% | 6,003 | 5,201 | $185K |
| 99443 | 1.3% | 3,167 | 2,873 | $153K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 6,950 | 6,680 | $64K |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 305 | 234 | $50K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | <1% | 842 | 760 | $50K |
| 93923 | <1% | 652 | 317 | $36K |
35 more codes
| 99442 | <1% | 1,012 | $34K | |
| 99205 | Prolong outpt/office vis | <1% | 214 | $20K |
| 95924 | <1% | 327 | $19K | |
| 95923 | <1% | 329 | $18K | |
| 81025 | <1% | 2,539 | $16K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 326 | $16K |
| 99152 | <1% | 361 | $12K | |
| 64493 | <1% | 100 | $9K | |
| 99441 | <1% | 222 | $8K | |
| 77002 | <1% | 188 | $7K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 110 | $6K |
| 64494 | <1% | 106 | $4K | |
| 20610 | <1% | 141 | $4K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,099 | $4K |
| 64635 | <1% | 17 | $4K | |
| 80305 | <1% | 461 | $3K | |
| 76942 | <1% | 107 | $3K | |
| 86769 | <1% | 62 | $2K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 53 | $2K |
| 93040 | <1% | 328 | $2K | |
| 62323 | <1% | 12 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,834 | $2K |
| 64483 | <1% | 13 | $1K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 109 | $1K |
| 95117 | <1% | 101 | $632.46 | |
| 20611 | <1% | 12 | $541.18 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 2,022 | $470.64 |
| 20552 | <1% | 13 | $319.56 | |
| 20553 | <1% | 12 | $217.69 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 238 | $160.10 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 388 | $76.02 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 13 | $23.18 |
| A4450 | Tape, non-waterproof, per 18 square inches | <1% | 758 | $10.21 |
| 99406 | 0% | 90 | $0.00 | |
| 99000 | 0% | 441 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialEVANS, IAN (CEO)